Theravance Biopharma (TBPH) Free Cash Flow Growth (1y) (2014 - 2026)
Theravance Biopharma (TBPH) Free Cash Flow Growth (1y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 7.12% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 1,092.51% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 66.37% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 3.98% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Theravance Biopharma | 864.82 Mn | 470.15 Mn | - | 70.26% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 70.26% |
| Dec 31, 2025 | -456.04% |
| Sep 30, 2025 | -24.89% |
| Jun 30, 2025 | 4,774.77% |
| Mar 31, 2025 | 3,966.94% |
| Dec 31, 2024 | 28.67% |
| Sep 30, 2024 | -107.86% |
| Jun 30, 2024 | 66.50% |
| Mar 31, 2024 | 90.85% |
| Dec 31, 2023 | -102.80% |
| Sep 30, 2023 | 84.79% |
| Jun 30, 2023 | 10.48% |
| Mar 31, 2023 | 53.80% |
| Dec 31, 2022 | 227.45% |
| Sep 30, 2022 | 64.54% |
| Jun 30, 2022 | 70.47% |
| Mar 31, 2022 | 63.26% |
| Dec 31, 2021 | 35.20% |
| Sep 30, 2021 | 41.22% |
| Jun 30, 2021 | 9.77% |